Consensus document on the use of sacubitril/valsartan in patients with heart failure: Consejo Interamericano de Falla Cardiaca e Hipertensi ón Pulmonar (CIFACAH) of the Inter-American Society of Cardiology (IASC)

Arch Cardiol Mex. 2023;93(Supl):1-12. doi: 10.24875/ACM.23000036.ABSTRACTHeart failure (HF) is a significant event for public health. It has a prevalence between 1-2%, mortality rate between 7-17%, and hospitalization between 32-44%. This implies a risk to health and quality of life, but also great financial efforts for health systems. Sacubitril/valsartan is a medication recognized for its efficacy, and this consensus seeks to synthesize the available information regarding its use for the benefit of patients. This document consists of a description of the epidemiology of HF, pharmacology of the drug, clinical trials, use of the drug in cases with reduced ejection fraction, mildly reduced ejection fraction and preserved ejection fraction, available literature on HF guidelines, recommendations and conclusions.PMID:37918409 | DOI:10.24875/ACM.23000036

Source: Archivos de Cardiologia de Mexico - November 2, 2023 Category: Cardiology Authors: Mario Speranza Clara Saldarriaga Carlos E Ramos Daniel Quesada V íctor Rossel Jaime R Ventura-Umanzor Freddy Pow-Chon Walter Alarco Yolanda Figueroa Antonio Maga ña Juan E G ómez-Mesa David Rodr íguez-García Source Type: research